Results 191 to 200 of about 24,826 (263)

Coronary Microvascular Dysfunction and Lipid Molecules: Pathophysiological Mechanisms, Clinical Assessment, and Therapeutic Implications. [PDF]

J Pers Med
Hafez A, Farina JM, Awad K, Pietri MP, Scalia IG, Sheashaa H, Abdelfattah FE, Razaghi M, Ahmed S, Ibrahim R, Simper D, Lester SJ, Tamarappoo B, Ayoub C, Arsanjani R.   +14 more
europepmc   +1 more source

Lipoprotein(a): Role in Cardiovascular Risk and Advances in Novel Therapeutics. [PDF]

Cureus
Murillo Sotela A, Orozco Loaiza G, Villalobos Villalobos P, Alfaro Guerra J.   +3 more
europepmc   +1 more source

Lipoprotein(a) and Risk of Treated Ventricular Arrhythmias in Heart Failure.

JAMA Netw Open
Ibrahim R, Dreher L, Nabi HA, Farina JM, Habib E, Pham HN, Tan MC, Noureldine HA, Ibrahim S, Bhakta M, Lee K, Sorajja D, Shen WK, Scott LR, Ayoub C, Arsanjani R, El Masry HZ.   +16 more
europepmc   +1 more source

Association Between Lipoprotein(a) Testing, Lipid-Lowering Therapy Intensification, and Low-Density Lipoprotein Cholesterol Goal Attainment: Findings From the Veterans Affairs Health System. [PDF]

J Am Heart Assoc
Parsa S, Shah P, Furst A, Dudum R, Din N, Maron D, Heidenreich P, Ward JH, Lozama A, Sandhu AT, Rodriguez F.   +10 more
europepmc   +1 more source

Lipoprotein(a) and the Risk of Heart Failure: A Dose-Response Meta-Analysis. [PDF]

Clin Cardiol
He Y, Liu J, Zhuang J, Hu H.
europepmc   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source